Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

Velden, V.H. van der
Sluijs-Geling, A. van der
Gibson, B.E.
Marvelde, J.G. Te
Hoogeveen, P.G.
Hop, W.C.J.
Wheatley, K.
Bierings, M.B.
Schuurhuis, G.J.
Graaf, S.S.N. de
Wering, E.R. van
Dongen, J.J.A.M. van

Open link

Publication date

January 2010

DOI

10.1038/leu.2010.153

Publisher

Springer Science and Business Media LLC

ISSN

0887-6924

Citation count (estimate)

Abstract

Item does not contain fulltextAnalysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85%+/-8% (s.e.) for MRD-negative patients (MRDor=0.5%; P<0.001), whereas overall survival was 95%+/-5%, 70%+/-10% and 40%+/-13%, respectively, (P<0.001). Multivariate analysis allowing for age, karyotype, FL...